Oculogica
Medical device company developing eye-tracking–based, non‑invasive diagnostic tests for concussion. Offers an in‑clinic objective assessment that analyzes eye movements to generate a multimetric score and a rapid portable sideline assessment that combines eye‑tracking metrics with symptom input. Has multiple FDA 510(k) clearances, peer‑reviewed publications, and collaborations with academic and military research groups.
Industries
Nr. of Employees
small (1-50)
Patents
Products
In-clinic objective eye-tracking concussion assessment device
A battery-powered clinic device that records high-volume eye-tracking data, analyzes cranial nerve–related eye movements, and produces an objective multimetric score and report without requiring a pre-injury baseline (typical assessment ~4 minutes).
Portable 90-second sideline concussion assessment
A rugged portable assessment that combines eye-tracking metrics with a brief symptom inventory to deliver a multimodal concussion score intended for sideline, pediatric, urgent care, and sports settings (approx. 90 seconds).
EyeBOX
EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an aid in diagnosis of concussion. It uses eye-tracking to provide objective information to aid in the assessment of patients with suspected concussion via an easy-to-take, 4-minute test. It is baseline-free and suitable for pediatrics ages 5 and older and adults up to 67 years of age.
SNAP™ Concussion Test®
SNAP™ Concussion Test® is a concussion testing product offered by Oculogica.
In-clinic objective eye-tracking concussion assessment device
A battery-powered clinic device that records high-volume eye-tracking data, analyzes cranial nerve–related eye movements, and produces an objective multimetric score and report without requiring a pre-injury baseline (typical assessment ~4 minutes).
Portable 90-second sideline concussion assessment
A rugged portable assessment that combines eye-tracking metrics with a brief symptom inventory to deliver a multimodal concussion score intended for sideline, pediatric, urgent care, and sports settings (approx. 90 seconds).
EyeBOX
EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an aid in diagnosis of concussion. It uses eye-tracking to provide objective information to aid in the assessment of patients with suspected concussion via an easy-to-take, 4-minute test. It is baseline-free and suitable for pediatrics ages 5 and older and adults up to 67 years of age.
SNAP™ Concussion Test®
SNAP™ Concussion Test® is a concussion testing product offered by Oculogica.
Services
Onsite or remote demonstrations and onboarding to illustrate device workflows, scoring outputs, and clinical applications.
Live training sessions and access to training materials (videos and case studies) for validated customers to support device operation and report interpretation.
Onsite or remote demonstrations and onboarding to illustrate device workflows, scoring outputs, and clinical applications.
Live training sessions and access to training materials (videos and case studies) for validated customers to support device operation and report interpretation.
Expertise Areas
- Objective concussion diagnostics
- Clinical validation and peer‑reviewed study support
- Regulatory (FDA 510(k)) submissions for diagnostic devices
- Deployment of portable medical devices in clinical and field settings
Key Technologies
- Eye-tracking (infrared, non‑spatially calibrated)
- Algorithmic eye-movement analysis
- Objective multimetric scoring (BOX score)
- Portable diagnostic hardware
News & Updates
FDA 510(k) clearance granted for a 90-second multimodal sideline concussion assessment combining eye-tracking and symptom input; reported diagnostic performance of 90% sensitivity and 94% specificity in press release.
Independent Department of Defense–led study compared three eye-tracking devices; reported highest diagnostic sensitivity in recent concussion and highest specificity in chronic cases for the in-clinic device, plus lowest poor-quality scan rate.
Announcement of expanded FDA label/clearance for the in-clinic objective eye-tracking device (reported April 2025 in site news).
Collection of 16+ peer‑reviewed publications on eye-tracking metrics for concussion and related neurologic assessments.
Reported six FDA clearances for concussion diagnostics across devices.
Reported 16 peer-reviewed publications validating eye-tracking approaches in concussion and neurologic assessment.
FDA 510(k) clearance granted for a 90-second multimodal sideline concussion assessment combining eye-tracking and symptom input; reported diagnostic performance of 90% sensitivity and 94% specificity in press release.
Independent Department of Defense–led study compared three eye-tracking devices; reported highest diagnostic sensitivity in recent concussion and highest specificity in chronic cases for the in-clinic device, plus lowest poor-quality scan rate.
Announcement of expanded FDA label/clearance for the in-clinic objective eye-tracking device (reported April 2025 in site news).
Collection of 16+ peer‑reviewed publications on eye-tracking metrics for concussion and related neurologic assessments.
Reported six FDA clearances for concussion diagnostics across devices.
Reported 16 peer-reviewed publications validating eye-tracking approaches in concussion and neurologic assessment.